Fuji Pharma Co., Ltd. (TYO:4554)
Japan
· Delayed Price · Currency is JPY 1,361.00
+4.00 (0.29%)
May 2, 2025, 3:30 PM JST
Fuji Pharma Income Statement
Financials in millions JPY. Fiscal year is October - September.
Millions JPY. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | 2015 - 2019 |
| Revenue | 48,392 | 46,138 | 40,889 | 35,426 | 33,990 | 33,793 | Upgrade
|
| Revenue Growth (YoY) | 16.22% | 12.84% | 15.42% | 4.23% | 0.58% | -6.85% | Upgrade
|
| Cost of Revenue | 28,796 | 28,294 | 24,374 | 20,867 | 19,239 | 18,921 | Upgrade
|
| Gross Profit | 19,596 | 17,844 | 16,515 | 14,559 | 14,751 | 14,872 | Upgrade
|
| Selling, General & Admin | 9,590 | 9,231 | 8,331 | 7,355 | 8,340 | 8,048 | Upgrade
|
| Research & Development | 3,401 | 3,401 | 3,184 | 2,485 | 2,446 | 3,060 | Upgrade
|
| Operating Expenses | 14,322 | 13,963 | 12,656 | 10,781 | 11,402 | 11,732 | Upgrade
|
| Operating Income | 5,274 | 3,881 | 3,859 | 3,778 | 3,349 | 3,140 | Upgrade
|
| Interest Expense | -233 | -196 | -121 | -77 | -53 | -37 | Upgrade
|
| Interest & Investment Income | - | - | 77 | 43 | 7 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 139 | 74 | 127 | 227 | -48 | -135 | Upgrade
|
| Other Non Operating Income (Expenses) | 39 | 53 | 212 | 39 | -6 | 14 | Upgrade
|
| EBT Excluding Unusual Items | 5,219 | 3,812 | 4,154 | 4,010 | 3,249 | 2,982 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 3,118 | - | - | 153 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 2 | 4 | Upgrade
|
| Asset Writedown | 638 | 572 | 364 | -288 | -33 | -69 | Upgrade
|
| Legal Settlements | - | - | -120 | - | - | - | Upgrade
|
| Other Unusual Items | -66 | 772 | - | - | -1 | - | Upgrade
|
| Pretax Income | 5,791 | 8,274 | 4,398 | 3,722 | 3,370 | 2,917 | Upgrade
|
| Income Tax Expense | 1,393 | 2,128 | 963 | 1,026 | 938 | 832 | Upgrade
|
| Net Income | 4,398 | 6,146 | 3,435 | 2,696 | 2,432 | 2,085 | Upgrade
|
| Net Income to Common | 4,398 | 6,146 | 3,435 | 2,696 | 2,432 | 2,085 | Upgrade
|
| Net Income Growth | -13.08% | 78.92% | 27.41% | 10.85% | 16.64% | -29.61% | Upgrade
|
| Shares Outstanding (Basic) | 24 | 24 | 24 | 24 | 27 | 31 | Upgrade
|
| Shares Outstanding (Diluted) | 24 | 24 | 24 | 24 | 27 | 31 | Upgrade
|
| Shares Change (YoY) | 0.05% | 0.04% | 0.03% | -9.58% | -13.77% | 2.06% | Upgrade
|
| EPS (Basic) | 180.88 | 252.81 | 141.35 | 110.98 | 90.52 | 66.92 | Upgrade
|
| EPS (Diluted) | 180.88 | 252.81 | 141.35 | 110.98 | 90.52 | 66.92 | Upgrade
|
| EPS Growth | -13.12% | 78.86% | 27.37% | 22.60% | 35.27% | -31.03% | Upgrade
|
| Free Cash Flow | - | 1,373 | -1,410 | -5,755 | 2,204 | 3,448 | Upgrade
|
| Free Cash Flow Per Share | - | 56.48 | -58.02 | -236.90 | 82.03 | 110.66 | Upgrade
|
| Dividend Per Share | 42.500 | 42.500 | 37.000 | 35.000 | 29.000 | 29.000 | Upgrade
|
| Dividend Growth | 14.87% | 14.87% | 5.71% | 20.69% | - | - | Upgrade
|
| Gross Margin | 40.49% | 38.67% | 40.39% | 41.10% | 43.40% | 44.01% | Upgrade
|
| Operating Margin | 10.90% | 8.41% | 9.44% | 10.66% | 9.85% | 9.29% | Upgrade
|
| Profit Margin | 9.09% | 13.32% | 8.40% | 7.61% | 7.16% | 6.17% | Upgrade
|
| Free Cash Flow Margin | - | 2.98% | -3.45% | -16.25% | 6.48% | 10.20% | Upgrade
|
| EBITDA | 9,118 | 7,561 | 6,882 | 6,523 | 5,455 | 5,197 | Upgrade
|
| EBITDA Margin | 18.84% | 16.39% | 16.83% | 18.41% | 16.05% | 15.38% | Upgrade
|
| D&A For EBITDA | 3,844 | 3,680 | 3,023 | 2,745 | 2,106 | 2,057 | Upgrade
|
| EBIT | 5,274 | 3,881 | 3,859 | 3,778 | 3,349 | 3,140 | Upgrade
|
| EBIT Margin | 10.90% | 8.41% | 9.44% | 10.66% | 9.85% | 9.29% | Upgrade
|
| Effective Tax Rate | 24.05% | 25.72% | 21.90% | 27.57% | 27.83% | 28.52% | Upgrade
|
Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.